Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.47)
# 305
Out of 5,113 analysts
67
Total ratings
59.57%
Success rate
19.92%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $17.00 | +17.65% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $77.35 | -1.75% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $11.27 | +24.22% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $134.78 | -25.81% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $27.94 | +10.95% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $16.05 | -43.93% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $32.51 | +1.51% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $162.38 | +17.01% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $96.24 | +3.91% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $22.28 | -14.72% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $378.03 | +3.17% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $64.46 | -14.68% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $99.74 | -44.86% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $137.24 | +16.58% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $567.83 | +17.99% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $6.55 | +205.34% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,402.51 | -0.18% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.84 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $46.48 | +93.63% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $224.84 | +20.09% | 4 | Dec 20, 2023 |
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $17.00
Upside: +17.65%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $77.35
Upside: -1.75%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $11.27
Upside: +24.22%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $134.78
Upside: -25.81%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $27.94
Upside: +10.95%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $16.05
Upside: -43.93%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $32.51
Upside: +1.51%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $162.38
Upside: +17.01%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $96.24
Upside: +3.91%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $22.28
Upside: -14.72%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $378.03
Upside: +3.17%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $64.46
Upside: -14.68%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $99.74
Upside: -44.86%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $137.24
Upside: +16.58%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $567.83
Upside: +17.99%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $6.55
Upside: +205.34%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,402.51
Upside: -0.18%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.84
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $46.48
Upside: +93.63%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $224.84
Upside: +20.09%